Reverse transcriptase-IN-1

• Description :

  Reverse transcriptase-IN-1 (Compound 12z), a diarylbenzopyrimidine (DABP) analogue, is a potent, orally active HIV-1 nonnucleoside reverse transcriptase inhibitor. Reverse transcriptase-IN-1 has antiviral activity with EC50 values of 3.4 nM, 4.3 nM and 3.6 nM for HIV-1 IIIB, E138K and K103N mutants, respectively. Reverse transcriptase-IN-1 also has an IC50of 13.7 nM against HIV-1 reverse transcriptase enzyme[1].

• UNSPSC :

  12352005

• Target :

  HIV

• Type :

  Reference compound

• Related Pathways :

  Anti-infection

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Infection

• Assay Protocol :

  https://www.medchemexpress.com/reverse-transcriptase-in-1.html

• Concentration :

  10mM

• Purity :

  98.08

• Solubility :

  DMSO : 12.5 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  N#CC1=CC=C(NC2=NC(NC3=C([N+]([O-])=O)C=C(/C=C/C#N)C=C3C)=C4C=CC=CC4=N2)C=C1

• Molecular Formula :

  C25H17N7O2

• Molecular Weight :

  447.45

• References & Citations :

  [1]Han S, et al. Molecular Hybridization-Inspired Optimization of Diarylbenzopyrimidines as HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors with Improved Activity against K103N and E138K Mutants and Pharmacokinetic Profiles. ACS Infect Dis. 2019 Oct 24.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  HIV-1

• CAS Number :

  [2380001-43-2]